Session Registration form 4
Event Timing: February 4, 2019
Event Address: EPHI auditorium
Contact us at : ESOG , Ras Desta Damtew Avenue
Tsehafi Tízaz Teferawork Keda Bldg (Near Ghion Hotel)
East Wing, 2nd Floor, Room no 7

Tel: 251-11-5506068/69

Email address *
Open for everyone interested
SESSION 1: Presentation on different topics with various professionals
Morning Session
Venue: EPHI Auditorium
Moderators: Dr. Abdulfetah Abdulkadir and Dr. Munir Kassa
1. Ethical opinions in OBGYN 8:30-9:15 by Peter Schwartz and colleagues
Moderator: Dr. Munir Kassa
Learning objectives:
 be able to solve maternal-fetal conflicts
 understand adolescent decision making in reproductive health
 Identify components of informed consent.
2. Cardiologist's approach to Risk Assessment of cardiac disease in pregnancy 9:15-10:00
By Dr. Dejuma Yadeta
Learning objectives:
 Identify which pregnancies are associated with high cardiovascular risk
 choose risk assessment models most appropriate for their patients
 Identify cardiac lesions in which pregnancy is contraindicated
3. The pregnant cardiac patients: Cardiac catastrophes 10:15 - 10:45 by Dr. Thut Teshome
Learning objectives:
 What are the riskiest cardiac conditions for anesthesia in pregnancy?
 What are the essential steps to optimize anesthetic care?
 How to manage cardiac catastrophe in labour and delivery?

4. Congenital Heart Disease (Cyanotic Vs. Non-cyanotic) in pregnancy 10:45-11:15 by Dr. Esubalew Woldeyes
Learning objectives:
 Describe common congenital defects in pregnancy
 Discuss unique challenges of the Eeisenmenger Syndrome patient
 Review management approach
5. Valvular disease of the heart in pregnancy 11:15 - 11:45 by Dr. J. Igor Iruretagoyena
Learning objectives:
 How does valve disease present in pregnancy?
 What kind of valve disease caries the highest Vs. lowest maternal risk
 How to best manage valve disease in pregnancy

Discussion 11:45 - 12:00

Afternoon 13:00 - 15:30
Moderators: Dr. Wondimu Gudu and Dr. Eyasu Mesfin
6. Controversies in anticoagulation in pregnancy 13:00 - 13:30 by Dr. J. Igor Iruretagoyena
Learning Objectives:
 Understand valvular heart disease guideline emphasizing on anti-coagulation
 Describe fetotoxicity of Warfarin anticoagulation
 Understand optimal management protocol during pregnancy
7. Recent Progress in Inflammation Associated Preterm Birth and Neonatal Sepsis 13:30 - 14:00 by Professor Catalin Buhimschi
 Become familiar with the concept of amniotic fluid biomarkers of inflammation/infection
 Outline the discovery process of cord blood biomarkers of neonatal sepsis
 Outline clinical management options
8. Preeclampsia: research update, challenges and new opportunities 14:00 - 14:30 by Professor Irina Buhimschi
Learning objectives:
 Review pathogenic pathways leading to preeclampsia/eclampsia
 Review the clinical classifications of hypertensive disorders of pregnancy and the implications of recent changes for different health care settings
 Introduce the notions of protein misfolding and proteostasis with relevance to preeclampsia and to other human diseases
 Summarize results of recent clinical studies aimed at improving diagnosis of preeclampsia to reduce severe morbidity and mortality
9. Management of Rh-alloimmunisation by Dr. Delayehu Bekele 14:30-15:00
Learning objectives:
 Be able to explain the evolving role of cfDNA in determining which patient should
receive antenatal Rhesus immune globulin
 Understand proper reporting and use of MCA Doppler and
 Understand the management of the alloimmunized pregnancy
10. Updates on the Management of contraception in women with medical conditions 15:00-15:30 by Dr. Sarah W. Prager
Learning objectives:
 Discuss current epidemiology of medical conditions among women who require contraception.
 Discuss effects of contraceptives on medical conditions and vice-versa.
 Update contraceptive options for women with medical conditions
11. Update on approach to evaluation and management of female factor infertility 15:30- 16:00 by Dr. Parul Katiyar
Learning objectives:
 Describe the current status and role of female factor infertility including epidemiology and etiologies.
 Discuss evaluation plan/algorism of female factor infertility.
 Discuss the medical and surgical management approaches to female factor infertility including their indications, outcome and limitations.
Discussion: 16:00 - 16:15
Tea and Coffee 16:15-16:30

Full Name *
Your answer
Telephone *
Your answer
Organization *
Your answer
A copy of your responses will be emailed to the address you provided.
Never submit passwords through Google Forms.
This content is neither created nor endorsed by Google. Report Abuse - Terms of Service